Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity. J of Skin [Internet]. 2023 Nov. 13 [cited 2025 Apr. 18];7(6):s274. Available from: https://skin.dermsquared.com/skin/article/view/2385